English
简体中文
Total: £ 56.28
Published Date: 2025-09-20 | Pages: 99 | Tables: 102 | Pharma & Healthcare
The global market for NK-1 Receptor Antagonists was valued at US$ 805 million in the year 2024 and is projected to reach a revised size of US$ 1266 million by 2031, growing at a CAGR of 6.8% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on NK-1 Receptor Antagonists competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
NK-1 receptor antagonists are a class of drugs that block the neurokinin-1 (NK1) receptors, which are activated by the neurotransmitter substance P. Substance P plays a key role in the body's vomiting reflex, as well as in pain perception and stress responses. By inhibiting NK1 receptors, these drugs are primarily used to prevent and treat nausea and vomiting, particularly those caused by chemotherapy, radiation therapy, or surgery. In 2024, the global sales volume of NK-1 receptor antagonists reached 3.65 million units, with an average price of 220 USD per unit.
Regional Market Landscape
NK-1 receptor antagonists exhibit a distinct regional distribution in the global market. North America accounts for 45% of the total market, driven primarily by the mature pharmaceutical R&D infrastructure and high treatment demand in the United States. Europe follows with a 28% share, led by Germany, France, and the United Kingdom, where healthcare insurance coverage and acceptance of innovative drugs are high. The Asia-Pacific region holds 20% of the market, with China, Japan, and India as core contributors, reflecting steady growth in demand due to the increasing prevalence of chronic diseases and cancer. Latin America and the Middle East & Africa together represent 7%, primarily supported by Brazil, Mexico, and South Africa, where market development is relatively slower due to limited healthcare coverage but potential for growth exists.
Key Manufacturers and Industry Competition
The NK-1 receptor antagonist industry demonstrates an oligopolistic competitive structure. Major manufacturers include global companies such as Merck, Glenmark, and Sandoz, alongside regional players like Fosun Pharma and Hengrui Medicine in China. Upstream, these companies rely on raw material suppliers such as Lonza and WuXi AppTec, while downstream distribution channels include hospitals, pharmacy chains, and specialized medical institutions. Competition extends beyond pricing and sales networks, focusing also on R&D pipelines and expansion into new indications. Strategic partnerships, mergers, and licensing agreements are employed to integrate the supply chain, enhance market share, and strengthen technological barriers.
Technology Trends and Innovation Directions
Technological development in NK-1 receptor antagonists focuses on improving drug selectivity, prolonging half-life, and enhancing oral bioavailability. Molecular design and structural optimization are central to R&D, leveraging high-throughput screening and computer-aided drug design to increase target affinity and specificity. Innovation in delivery systems, including nanoparticle carriers and long-acting formulations, aims to improve patient adherence. Future innovations also involve combination therapies with other mechanisms and the development of personalized medicine approaches to meet the needs of diverse patient populations.
Policy and Industry Development Drivers
Healthcare policies and regulatory frameworks play a key role in the development of the NK-1 receptor antagonist market worldwide. The United States and Europe maintain strict but transparent approval systems that accelerate the launch of innovative drugs, while China encourages R&D through policies supporting innovation and generic consistency evaluation. Reimbursement policies and patient affordability directly affect market penetration, while updates to clinical guidelines and health management programs indirectly expand demand. Policy support and industry standardization drive higher market concentration and accelerate technological innovation.
Future Outlook
With the global increase in chronic disease and cancer patient populations, the NK-1 receptor antagonist market is expected to maintain steady long-term growth. Technological innovation will enhance drug efficacy, improve patient adherence, and reduce side effects and treatment costs. Integration of the supply chain and international expansion will strengthen corporate competitiveness, and regional market differentiation strategies will become a focus for development. Overall, the industry outlook is positive, with the next decade likely to be dominated by high-value innovative drugs alongside cross-border collaboration and regional market expansion.
Report Scope
This report aims to provide a comprehensive presentation of the global market for NK-1 Receptor Antagonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NK-1 Receptor Antagonists.
The NK-1 Receptor Antagonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global NK-1 Receptor Antagonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NK-1 Receptor Antagonists manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Merck
TerSera Therapeutics
Helsinn Healthcare
Heron Therapeutics
Sandoz
Glenmark
Torrent Pharmaceuticals
Steriscience
Mylan
Fresenius
MSN
Teva
Eugia Pharma
Lupin
Dr. Reddy's Laboratories
Chia Tai Tianqing Pharmaceutical
Qilu Pharmaceutical
Beijing Sihuan Pharmaceutical
Yichang Humanwell Pharmaceutical
Hansoh Pharma
Segment by Type
Aprepitant
Rolapitant
Fosaprepitant
Netupitant
Maropitant
Other
Segment by Application
Chemotherapy-induced Nausea and Vomiting (CINV)
Postoperative Nausea and Vomiting (PONV)
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of NK-1 Receptor Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 NK-1 Receptor Antagonists Market Overview
1.1 Product Definition
1.2 NK-1 Receptor Antagonists by Type
1.2.1 Global NK-1 Receptor Antagonists Market Value Comparison by Type (2024 VS 2031)
1.2.2 Aprepitant
1.2.3 Rolapitant
1.2.4 Fosaprepitant
1.2.5 Netupitant
1.2.6 Maropitant
1.2.7 Other
1.3 NK-1 Receptor Antagonists by Application
1.3.1 Global NK-1 Receptor Antagonists Market Value by Application (2024 VS 2031)
1.3.2 Chemotherapy-induced Nausea and Vomiting (CINV)
1.3.3 Postoperative Nausea and Vomiting (PONV)
1.3.4 Other
1.4 Global NK-1 Receptor Antagonists Market Size Estimates and Forecasts
1.4.1 Global NK-1 Receptor Antagonists Revenue 2020-2031
1.4.2 Global NK-1 Receptor Antagonists Sales 2020-2031
1.4.3 Global NK-1 Receptor Antagonists Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 NK-1 Receptor Antagonists Market Competition by Manufacturers
2.1 Global NK-1 Receptor Antagonists Sales Market Share by Manufacturers (2020-2025)
2.2 Global NK-1 Receptor Antagonists Revenue Market Share by Manufacturers (2020-2025)
2.3 Global NK-1 Receptor Antagonists Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of NK-1 Receptor Antagonists, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of NK-1 Receptor Antagonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of NK-1 Receptor Antagonists, Product Type & Application
2.7 Global Key Manufacturers of NK-1 Receptor Antagonists, Date of Enter into This Industry
2.8 Global NK-1 Receptor Antagonists Market Competitive Situation and Trends
2.8.1 Global NK-1 Receptor Antagonists Market Concentration Rate
2.8.2 The Global 5 and 10 Largest NK-1 Receptor Antagonists Players Market Share by Revenue
2.8.3 Global NK-1 Receptor Antagonists Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global NK-1 Receptor Antagonists Market Scenario by Region
3.1 Global NK-1 Receptor Antagonists Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global NK-1 Receptor Antagonists Sales by Region: 2020-2031
3.2.1 Global NK-1 Receptor Antagonists Sales by Region: 2020-2025
3.2.2 Global NK-1 Receptor Antagonists Sales by Region: 2026-2031
3.3 Global NK-1 Receptor Antagonists Revenue by Region: 2020-2031
3.3.1 Global NK-1 Receptor Antagonists Revenue by Region: 2020-2025
3.3.2 Global NK-1 Receptor Antagonists Revenue by Region: 2026-2031
3.4 North America NK-1 Receptor Antagonists Market Facts & Figures by Country
3.4.1 North America NK-1 Receptor Antagonists Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America NK-1 Receptor Antagonists Sales by Country (2020-2031)
3.4.3 North America NK-1 Receptor Antagonists Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe NK-1 Receptor Antagonists Market Facts & Figures by Country
3.5.1 Europe NK-1 Receptor Antagonists Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe NK-1 Receptor Antagonists Sales by Country (2020-2031)
3.5.3 Europe NK-1 Receptor Antagonists Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific NK-1 Receptor Antagonists Market Facts & Figures by Region
3.6.1 Asia Pacific NK-1 Receptor Antagonists Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific NK-1 Receptor Antagonists Sales by Region (2020-2031)
3.6.3 Asia Pacific NK-1 Receptor Antagonists Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America NK-1 Receptor Antagonists Market Facts & Figures by Country
3.7.1 Latin America NK-1 Receptor Antagonists Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America NK-1 Receptor Antagonists Sales by Country (2020-2031)
3.7.3 Latin America NK-1 Receptor Antagonists Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa NK-1 Receptor Antagonists Market Facts & Figures by Country
3.8.1 Middle East and Africa NK-1 Receptor Antagonists Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2020-2031)
3.8.3 Middle East and Africa NK-1 Receptor Antagonists Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global NK-1 Receptor Antagonists Sales by Type (2020-2031)
4.1.1 Global NK-1 Receptor Antagonists Sales by Type (2020-2025)
4.1.2 Global NK-1 Receptor Antagonists Sales by Type (2026-2031)
4.1.3 Global NK-1 Receptor Antagonists Sales Market Share by Type (2020-2031)
4.2 Global NK-1 Receptor Antagonists Revenue by Type (2020-2031)
4.2.1 Global NK-1 Receptor Antagonists Revenue by Type (2020-2025)
4.2.2 Global NK-1 Receptor Antagonists Revenue by Type (2026-2031)
4.2.3 Global NK-1 Receptor Antagonists Revenue Market Share by Type (2020-2031)
4.3 Global NK-1 Receptor Antagonists Price by Type (2020-2031)
5 Segment by Application
5.1 Global NK-1 Receptor Antagonists Sales by Application (2020-2031)
5.1.1 Global NK-1 Receptor Antagonists Sales by Application (2020-2025)
5.1.2 Global NK-1 Receptor Antagonists Sales by Application (2026-2031)
5.1.3 Global NK-1 Receptor Antagonists Sales Market Share by Application (2020-2031)
5.2 Global NK-1 Receptor Antagonists Revenue by Application (2020-2031)
5.2.1 Global NK-1 Receptor Antagonists Revenue by Application (2020-2025)
5.2.2 Global NK-1 Receptor Antagonists Revenue by Application (2026-2031)
5.2.3 Global NK-1 Receptor Antagonists Revenue Market Share by Application (2020-2031)
5.3 Global NK-1 Receptor Antagonists Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck NK-1 Receptor Antagonists Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 TerSera Therapeutics
6.2.1 TerSera Therapeutics Company Information
6.2.2 TerSera Therapeutics Description and Business Overview
6.2.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.2.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
6.2.5 TerSera Therapeutics Recent Developments/Updates
6.3 Helsinn Healthcare
6.3.1 Helsinn Healthcare Company Information
6.3.2 Helsinn Healthcare Description and Business Overview
6.3.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
6.3.5 Helsinn Healthcare Recent Developments/Updates
6.4 Heron Therapeutics
6.4.1 Heron Therapeutics Company Information
6.4.2 Heron Therapeutics Description and Business Overview
6.4.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
6.4.5 Heron Therapeutics Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Company Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Glenmark
6.6.1 Glenmark Company Information
6.6.2 Glenmark Description and Business Overview
6.6.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
6.6.5 Glenmark Recent Developments/Updates
6.7 Torrent Pharmaceuticals
6.7.1 Torrent Pharmaceuticals Company Information
6.7.2 Torrent Pharmaceuticals Description and Business Overview
6.7.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
6.7.5 Torrent Pharmaceuticals Recent Developments/Updates
6.8 Steriscience
6.8.1 Steriscience Company Information
6.8.2 Steriscience Description and Business Overview
6.8.3 Steriscience NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
6.8.5 Steriscience Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Company Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Fresenius
6.10.1 Fresenius Company Information
6.10.2 Fresenius Description and Business Overview
6.10.3 Fresenius NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Fresenius NK-1 Receptor Antagonists Product Portfolio
6.10.5 Fresenius Recent Developments/Updates
6.11 MSN
6.11.1 MSN Company Information
6.11.2 MSN Description and Business Overview
6.11.3 MSN NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.11.4 MSN NK-1 Receptor Antagonists Product Portfolio
6.11.5 MSN Recent Developments/Updates
6.12 Teva
6.12.1 Teva Company Information
6.12.2 Teva Description and Business Overview
6.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
6.12.5 Teva Recent Developments/Updates
6.13 Eugia Pharma
6.13.1 Eugia Pharma Company Information
6.13.2 Eugia Pharma Description and Business Overview
6.13.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
6.13.5 Eugia Pharma Recent Developments/Updates
6.14 Lupin
6.14.1 Lupin Company Information
6.14.2 Lupin Description and Business Overview
6.14.3 Lupin NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Lupin NK-1 Receptor Antagonists Product Portfolio
6.14.5 Lupin Recent Developments/Updates
6.15 Dr. Reddy's Laboratories
6.15.1 Dr. Reddy's Laboratories Company Information
6.15.2 Dr. Reddy's Laboratories Description and Business Overview
6.15.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
6.15.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.16 Chia Tai Tianqing Pharmaceutical
6.16.1 Chia Tai Tianqing Pharmaceutical Company Information
6.16.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.16.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.16.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.17 Qilu Pharmaceutical
6.17.1 Qilu Pharmaceutical Company Information
6.17.2 Qilu Pharmaceutical Description and Business Overview
6.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.17.5 Qilu Pharmaceutical Recent Developments/Updates
6.18 Beijing Sihuan Pharmaceutical
6.18.1 Beijing Sihuan Pharmaceutical Company Information
6.18.2 Beijing Sihuan Pharmaceutical Description and Business Overview
6.18.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.18.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates
6.19 Yichang Humanwell Pharmaceutical
6.19.1 Yichang Humanwell Pharmaceutical Company Information
6.19.2 Yichang Humanwell Pharmaceutical Description and Business Overview
6.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.19.5 Yichang Humanwell Pharmaceutical Recent Developments/Updates
6.20 Hansoh Pharma
6.20.1 Hansoh Pharma Company Information
6.20.2 Hansoh Pharma Description and Business Overview
6.20.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
6.20.5 Hansoh Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 NK-1 Receptor Antagonists Industry Chain Analysis
7.2 NK-1 Receptor Antagonists Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 NK-1 Receptor Antagonists Production Mode & Process Analysis
7.4 NK-1 Receptor Antagonists Sales and Marketing
7.4.1 NK-1 Receptor Antagonists Sales Channels
7.4.2 NK-1 Receptor Antagonists Distributors
7.5 NK-1 Receptor Antagonists Customer Analysis
8 NK-1 Receptor Antagonists Market Dynamics
8.1 NK-1 Receptor Antagonists Industry Trends
8.2 NK-1 Receptor Antagonists Market Drivers
8.3 NK-1 Receptor Antagonists Market Challenges
8.4 NK-1 Receptor Antagonists Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global NK-1 Receptor Antagonists Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global NK-1 Receptor Antagonists Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global NK-1 Receptor Antagonists Market Competitive Situation by Manufacturers in 2024
Table 4. Global NK-1 Receptor Antagonists Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global NK-1 Receptor Antagonists Sales Market Share by Manufacturers (2020-2025)
Table 6. Global NK-1 Receptor Antagonists Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global NK-1 Receptor Antagonists Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market NK-1 Receptor Antagonists Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of NK-1 Receptor Antagonists, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of NK-1 Receptor Antagonists, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of NK-1 Receptor Antagonists, Product Type & Application
Table 12. Global Key Manufacturers of NK-1 Receptor Antagonists, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global NK-1 Receptor Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NK-1 Receptor Antagonists as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global NK-1 Receptor Antagonists Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global NK-1 Receptor Antagonists Sales by Region (2020-2025) & (K Units)
Table 18. Global NK-1 Receptor Antagonists Sales Market Share by Region (2020-2025)
Table 19. Global NK-1 Receptor Antagonists Sales by Region (2026-2031) & (K Units)
Table 20. Global NK-1 Receptor Antagonists Sales Market Share by Region (2026-2031)
Table 21. Global NK-1 Receptor Antagonists Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2020-2025)
Table 23. Global NK-1 Receptor Antagonists Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global NK-1 Receptor Antagonists Revenue Market Share by Region (2026-2031)
Table 25. North America NK-1 Receptor Antagonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America NK-1 Receptor Antagonists Sales by Country (2020-2025) & (K Units)
Table 27. North America NK-1 Receptor Antagonists Sales by Country (2026-2031) & (K Units)
Table 28. North America NK-1 Receptor Antagonists Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America NK-1 Receptor Antagonists Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe NK-1 Receptor Antagonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe NK-1 Receptor Antagonists Sales by Country (2020-2025) & (K Units)
Table 32. Europe NK-1 Receptor Antagonists Sales by Country (2026-2031) & (K Units)
Table 33. Europe NK-1 Receptor Antagonists Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe NK-1 Receptor Antagonists Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific NK-1 Receptor Antagonists Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific NK-1 Receptor Antagonists Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific NK-1 Receptor Antagonists Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific NK-1 Receptor Antagonists Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific NK-1 Receptor Antagonists Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America NK-1 Receptor Antagonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America NK-1 Receptor Antagonists Sales by Country (2020-2025) & (K Units)
Table 42. Latin America NK-1 Receptor Antagonists Sales by Country (2026-2031) & (K Units)
Table 43. Latin America NK-1 Receptor Antagonists Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America NK-1 Receptor Antagonists Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa NK-1 Receptor Antagonists Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa NK-1 Receptor Antagonists Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa NK-1 Receptor Antagonists Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global NK-1 Receptor Antagonists Sales (K Units) by Type (2020-2025)
Table 51. Global NK-1 Receptor Antagonists Sales (K Units) by Type (2026-2031)
Table 52. Global NK-1 Receptor Antagonists Sales Market Share by Type (2020-2025)
Table 53. Global NK-1 Receptor Antagonists Sales Market Share by Type (2026-2031)
Table 54. Global NK-1 Receptor Antagonists Revenue (US$ Million) by Type (2020-2025)
Table 55. Global NK-1 Receptor Antagonists Revenue (US$ Million) by Type (2026-2031)
Table 56. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2020-2025)
Table 57. Global NK-1 Receptor Antagonists Revenue Market Share by Type (2026-2031)
Table 58. Global NK-1 Receptor Antagonists Price (US$/Unit) by Type (2020-2025)
Table 59. Global NK-1 Receptor Antagonists Price (US$/Unit) by Type (2026-2031)
Table 60. Global NK-1 Receptor Antagonists Sales (K Units) by Application (2020-2025)
Table 61. Global NK-1 Receptor Antagonists Sales (K Units) by Application (2026-2031)
Table 62. Global NK-1 Receptor Antagonists Sales Market Share by Application (2020-2025)
Table 63. Global NK-1 Receptor Antagonists Sales Market Share by Application (2026-2031)
Table 64. Global NK-1 Receptor Antagonists Revenue (US$ Million) by Application (2020-2025)
Table 65. Global NK-1 Receptor Antagonists Revenue (US$ Million) by Application (2026-2031)
Table 66. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2020-2025)
Table 67. Global NK-1 Receptor Antagonists Revenue Market Share by Application (2026-2031)
Table 68. Global NK-1 Receptor Antagonists Price (US$/Unit) by Application (2020-2025)
Table 69. Global NK-1 Receptor Antagonists Price (US$/Unit) by Application (2026-2031)
Table 70. Merck Company Information
Table 71. Merck Description and Business Overview
Table 72. Merck NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Merck NK-1 Receptor Antagonists Product
Table 74. Merck Recent Developments/Updates
Table 75. TerSera Therapeutics Company Information
Table 76. TerSera Therapeutics Description and Business Overview
Table 77. TerSera Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. TerSera Therapeutics NK-1 Receptor Antagonists Product
Table 79. TerSera Therapeutics Recent Developments/Updates
Table 80. Helsinn Healthcare Company Information
Table 81. Helsinn Healthcare Description and Business Overview
Table 82. Helsinn Healthcare NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Helsinn Healthcare NK-1 Receptor Antagonists Product
Table 84. Helsinn Healthcare Recent Developments/Updates
Table 85. Heron Therapeutics Company Information
Table 86. Heron Therapeutics Description and Business Overview
Table 87. Heron Therapeutics NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Heron Therapeutics NK-1 Receptor Antagonists Product
Table 89. Heron Therapeutics Recent Developments/Updates
Table 90. Sandoz Company Information
Table 91. Sandoz Description and Business Overview
Table 92. Sandoz NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Sandoz NK-1 Receptor Antagonists Product
Table 94. Sandoz Recent Developments/Updates
Table 95. Glenmark Company Information
Table 96. Glenmark Description and Business Overview
Table 97. Glenmark NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Glenmark NK-1 Receptor Antagonists Product
Table 99. Glenmark Recent Developments/Updates
Table 100. Torrent Pharmaceuticals Company Information
Table 101. Torrent Pharmaceuticals Description and Business Overview
Table 102. Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Torrent Pharmaceuticals NK-1 Receptor Antagonists Product
Table 104. Torrent Pharmaceuticals Recent Developments/Updates
Table 105. Steriscience Company Information
Table 106. Steriscience Description and Business Overview
Table 107. Steriscience NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Steriscience NK-1 Receptor Antagonists Product
Table 109. Steriscience Recent Developments/Updates
Table 110. Mylan Company Information
Table 111. Mylan Description and Business Overview
Table 112. Mylan NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Mylan NK-1 Receptor Antagonists Product
Table 114. Mylan Recent Developments/Updates
Table 115. Fresenius Company Information
Table 116. Fresenius Description and Business Overview
Table 117. Fresenius NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Fresenius NK-1 Receptor Antagonists Product
Table 119. Fresenius Recent Developments/Updates
Table 120. MSN Company Information
Table 121. MSN Description and Business Overview
Table 122. MSN NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. MSN NK-1 Receptor Antagonists Product
Table 124. MSN Recent Developments/Updates
Table 125. Teva Company Information
Table 126. Teva Description and Business Overview
Table 127. Teva NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Teva NK-1 Receptor Antagonists Product
Table 129. Teva Recent Developments/Updates
Table 130. Eugia Pharma Company Information
Table 131. Eugia Pharma Description and Business Overview
Table 132. Eugia Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Eugia Pharma NK-1 Receptor Antagonists Product
Table 134. Eugia Pharma Recent Developments/Updates
Table 135. Lupin Company Information
Table 136. Lupin Description and Business Overview
Table 137. Lupin NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Lupin NK-1 Receptor Antagonists Product
Table 139. Lupin Recent Developments/Updates
Table 140. Dr. Reddy's Laboratories Company Information
Table 141. Dr. Reddy's Laboratories Description and Business Overview
Table 142. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product
Table 144. Dr. Reddy's Laboratories Recent Developments/Updates
Table 145. Chia Tai Tianqing Pharmaceutical Company Information
Table 146. Chia Tai Tianqing Pharmaceutical Description and Business Overview
Table 147. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product
Table 149. Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
Table 150. Qilu Pharmaceutical Company Information
Table 151. Qilu Pharmaceutical Description and Business Overview
Table 152. Qilu Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 153. Qilu Pharmaceutical NK-1 Receptor Antagonists Product
Table 154. Qilu Pharmaceutical Recent Developments/Updates
Table 155. Beijing Sihuan Pharmaceutical Company Information
Table 156. Beijing Sihuan Pharmaceutical Description and Business Overview
Table 157. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 158. Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product
Table 159. Beijing Sihuan Pharmaceutical Recent Developments/Updates
Table 160. Yichang Humanwell Pharmaceutical Company Information
Table 161. Yichang Humanwell Pharmaceutical Description and Business Overview
Table 162. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 163. Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product
Table 164. Yichang Humanwell Pharmaceutical Recent Developments/Updates
Table 165. Hansoh Pharma Company Information
Table 166. Hansoh Pharma Description and Business Overview
Table 167. Hansoh Pharma NK-1 Receptor Antagonists Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 168. Hansoh Pharma NK-1 Receptor Antagonists Product
Table 169. Hansoh Pharma Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. NK-1 Receptor Antagonists Distributors List
Table 173. NK-1 Receptor Antagonists Customers List
Table 174. NK-1 Receptor Antagonists Market Trends
Table 175. NK-1 Receptor Antagonists Market Drivers
Table 176. NK-1 Receptor Antagonists Market Challenges
Table 177. NK-1 Receptor Antagonists Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
Table 181. Authors List of This Report
List of Figures
Figure 1. Product Picture of NK-1 Receptor Antagonists
Figure 2. Global NK-1 Receptor Antagonists Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global NK-1 Receptor Antagonists Market Share by Type: 2024 & 2031
Figure 4. Aprepitant Product Picture
Figure 5. Rolapitant Product Picture
Figure 6. Fosaprepitant Product Picture
Figure 7. Netupitant Product Picture
Figure 8. Maropitant Product Picture
Figure 9. Other Product Picture
Figure 10. Global NK-1 Receptor Antagonists Market Value by Application (2020-2031) & (US$ Million)
Figure 11. Global NK-1 Receptor Antagonists Market Share by Application: 2024 & 2031
Figure 12. Chemotherapy-induced Nausea and Vomiting (CINV)
Figure 13. Postoperative Nausea and Vomiting (PONV)
Figure 14. Other
Figure 15. Global NK-1 Receptor Antagonists Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global NK-1 Receptor Antagonists Market Size (2020-2031) & (US$ Million)
Figure 17. Global NK-1 Receptor Antagonists Sales (2020-2031) & (K Units)
Figure 18. Global NK-1 Receptor Antagonists Average Price (US$/Unit) & (2020-2031)
Figure 19. NK-1 Receptor Antagonists Report Years Considered
Figure 20. NK-1 Receptor Antagonists Sales Share by Manufacturers in 2024
Figure 21. Global NK-1 Receptor Antagonists Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest NK-1 Receptor Antagonists Players: Market Share by Revenue in NK-1 Receptor Antagonists in 2024
Figure 23. NK-1 Receptor Antagonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global NK-1 Receptor Antagonists Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America NK-1 Receptor Antagonists Sales Market Share by Country (2020-2031)
Figure 26. North America NK-1 Receptor Antagonists Revenue Market Share by Country (2020-2031)
Figure 27. United States NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe NK-1 Receptor Antagonists Sales Market Share by Country (2020-2031)
Figure 30. Europe NK-1 Receptor Antagonists Revenue Market Share by Country (2020-2031)
Figure 31. Germany NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific NK-1 Receptor Antagonists Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific NK-1 Receptor Antagonists Revenue Market Share by Region (2020-2031)
Figure 38. China NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America NK-1 Receptor Antagonists Sales Market Share by Country (2020-2031)
Figure 46. Latin America NK-1 Receptor Antagonists Revenue Market Share by Country (2020-2031)
Figure 47. Mexico NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Colombia NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Middle East and Africa NK-1 Receptor Antagonists Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa NK-1 Receptor Antagonists Revenue Market Share by Country (2020-2031)
Figure 53. Turkey NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. UAE NK-1 Receptor Antagonists Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Global Sales Market Share of NK-1 Receptor Antagonists by Type (2020-2031)
Figure 57. Global Revenue Market Share of NK-1 Receptor Antagonists by Type (2020-2031)
Figure 58. Global NK-1 Receptor Antagonists Price (US$/Unit) by Type (2020-2031)
Figure 59. Global Sales Market Share of NK-1 Receptor Antagonists by Application (2020-2031)
Figure 60. Global Revenue Market Share of NK-1 Receptor Antagonists by Application (2020-2031)
Figure 61. Global NK-1 Receptor Antagonists Price (US$/Unit) by Application (2020-2031)
Figure 62. NK-1 Receptor Antagonists Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
